X염색체유전 선천안구진탕 환자에서 GPR143유전자의 새로운 돌연변이를 찾아 최초로 보고한 논문입니다.
https://www.ncbi.nlm.nih.gov/pubmed/27672609
건양의대 김안과병원 사시&소아안과센터 전문의
시신경형성부전은
저시력환자들을 접하는 의사 및 관계자들을 위한 교과서입니다.
문남주,김응수,박신혜 공저
Optic neuritis treatment trials (ONTT) have reported that systemic corticosteroid did not improve final visual acuity. As a result, ophthalmologists should explain hazards and benefits of systemic corticosteroid, and the decision is up to the patients.
I think that this situation is kind of awkward because the patients don’t have any idea about the treatment of optic neuritis and doctors may seem to be incompetent.
During my short term training in Kinki University, Japan, the professor Nakao has recommended systemic corticosteroid to the patients.
That’s because the possibility of neuromyelitis optica (NMO).
The patients of NMO should be treated using systemic corticosteroid as soon as possible. If the patients do not respond, plasma exchange should be considered.
유럽에서 상용화되어 있는 Raxone (Idebenone)에 대한 연구를 진행중에 있습니다.
근시진행을 늦추고자 저농도아트로핀 사용에 대한 연구를 진행하고 있습니다.